Page 127 - 南京医科大学自然版

第45卷第3期 李 奇，秦亚娟，唐立钧. 帕金森病标志物α⁃突触核蛋白聚集抑制剂的研究进展［J］.
2025年3月 南京医科大学学报（自然科学版），2025，45（3）：404-417 ·415 ·

pathways［J］. Mol Neurobiol，2022，59（1）：405-419 ［29］ XILOURI M，BREKK O R，STEFANIS L. α ⁃ Synuclein
［17］SCHASER A J，OSTERBERG V R，DENT S E，et al. Alpha⁃ and protein degradation systems ：a reciprocal relation⁃
synuclein is a DNA binding protein that modulates DNA ship［J］. Mol Neurobiol，2013，47（2）：537-551
repair with implications for Lewy body disorders［J］. Sci ［30］WANG Q Q，LIU Y J，ZHOU J W. Neuroinflammation in
Rep，2019，9（1）：10919 Parkinson’s disease and its potential as therapeutic tar⁃
［18］KONTOPOULOS E，PARVIN J D，FEANY M B. Alpha⁃ get［J］. Transl Neurodegener，2015，4：19
synuclein acts in the nucleus to inhibit histone acetyla⁃ ［31］LONG H F，ZHANG S N，ZENG S Y，et al. Interaction of
tion and promote neurotoxicity［J］. Hum Mol Genet， RAGE with α ⁃ synuclein fibrils mediates inflammatory
2006，15（20）：3012-3023 response of microglia［J］. Cell Rep，2022，40（12）：
［19］DAGRA A，MILLER D R，LIN M，et al. α ⁃Synuclein⁃ 111401
induced dysregulation of neuronal activity contributes to ［32］ANTONSCHMIDT L，MATTHES D，DERVIŞO LU R，et
murine dopamine neuron vulnerability［J］. NPJ Parkin⁃ al. The clinical drug candidate anle138b binds in a cavity
sons Dis，2021，7（1）：76 of lipidic α⁃synuclein fibrils［J］. Nat Commun，2022，13
［20］CHOI M L，CHAPPARD A，SINGH B P，et al. Pathologi⁃ （1）：5385
cal structural conversion of α⁃synuclein at the mitochon⁃ ［33］WAGNER J，RYAZANOV S，LEONOV A，et al. An⁃
dria induces neuronal toxicity［J］. Nat Neurosci，2022，25 le138b：a novel oligomer modulator for disease⁃modifying
（9）：1134-1148 therapy of neurodegenerative diseases such as prion and
［21］MARTINEZ T N，GREENAMYRE J T. Toxin models of Parkinson’s disease［J］. Acta Neuropathol，2013，125
mitochondrial dysfunction in Parkinson’s disease［J］. An⁃ （6）：795-813
tioxid Redox Signal，2012，16（9）：920-934 ［34］LEVIN J，SCHMIDT F，BOEHM C，et al. The oligomer
［22］ NAKAMURA K，NEMANI V M，AZARBAL F，et al. modulator anle138b inhibits disease progression in a
Direct membrane association drives mitochondrial fission Parkinson mouse model even with treatment started after
by the Parkinsons disease⁃associated protein alpha⁃synu⁃ disease onset［J］. Acta Neuropathol，2014，127（5）：779-
clein［J］. J Biol Chem，2011，286（23）：20710-20726 780
［23］CHEN L N，XIE Z G，TURKSON S，et al. A53T human ［35］HERAS⁃GARVIN A，WECKBECKER D，RYAZANOV S，
α ⁃ synuclein overexpression in transgenic mice induces et al. Anle138b modulates α ⁃ synuclein oligomerization
pervasive mitochondria macroautophagy defects preceding and prevents motor decline and neurodegeneration in a
dopamine neuron degeneration［J］. J Neurosci，2015，35 mouse model of multiple system atrophy［J］. Mov Disord，
（3）：890-905 2019，34（2）：255-263
［24］ DI MAIO R，BARRETT P J，HOFFMAN E K，et al. α⁃ ［36］BRENDEL M，DEUSSING M，BLUME T，et al. Late⁃stage
Synuclein binds to TOM20 and inhibits mitochondrial anle138b treatment ameliorates tau pathology and meta⁃
protein import in Parkinson’s disease［J］. Sci Transl bolic decline in a mouse model of human Alzheimer’s
Med，2016，8（342）：342ra78 disease tau［J］. Alzheimers Res Ther，2019，11（1）：67
［25］SPRENKLE N T，SIMS S G，SÁNCHEZ C L，et al. Endo⁃ ［37］ALECU J E，SIGUTOVA V，BRAZDIS R M，et al. NPT100⁃
plasmic reticulum stress and inflammation in the central 18A reduces mitochondrial oxidative stress and rescues
nervous system［J］. Mol Neurodegener，2017，12（1）：42 neuronal cell death in a human iPSC⁃based model of Par⁃
［26］COLLA E，JENSEN P H，PLETNIKOVA O，et al. Accu⁃ kinson’s disease［J］. Research Square，2023，DOI：
mulation of toxic α⁃synuclein oligomer within endoplas⁃ 10.21203/RS.3.RS⁃3311240/V1
mic reticulum occurs in α⁃synucleinopathy in vivo［J］. J ［38］WRASIDLO W，TSIGELNY I F，PRICE D L，et al. A de
Neurosci，2012，32（10）：3301-3305 novo compound targeting α⁃synuclein improves deficits in
［27］FUJITA Y，OHAMA E，TAKATAMA M，et al. Fragmenta⁃ models of Parkinson’s disease［J］. Brain，2016，139（Pt
tion of Golgi apparatus of nigral neurons with alpha⁃synu⁃ 12）：3217-3236
clein ⁃ positive inclusions in patients with Parkinson’s ［39］DAS D，BHARADWAZ P，MATTAPARTHI V S K. Com⁃
disease［J］. Acta Neuropathol，2006，112（3）：261-265 putational investigation on the effect of the peptidomimetic
［28］COOPER A A，GITLER A D，CASHIKAR A，et al. Alpha⁃ inhibitors（NPT100⁃18A and NPT200⁃11）on the α⁃synu⁃
synuclein blocks ER ⁃ Golgi traffic and Rab1 rescues clein and lipid membrane interactions［J］. J Biomol
neuron loss in Parkinson’s models［J］. Science，2006，313 Struct Dyn，2024，42（21）：11471-11482
（5785）：324-328 ［40］PRICE D L，KOIKE M A，KHAN A，et al. The small mole⁃